Cowen Lowers TherapeuticsMD (NASDAQ:TXMD) Price Target to $9.00
TherapeuticsMD (NASDAQ:TXMD) had its price target cut by Cowen from $16.00 to $9.00 in a research note issued on Tuesday, The Fly reports. The firm presently has an “outperform” rating on the stock. Cowen’s price target suggests a potential upside of 254.33% from the company’s current price.
Several other equities analysts have also recently issued reports on TXMD. Zacks Investment Research raised TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Saturday, April 27th. Cantor Fitzgerald reaffirmed a “positive” rating on shares of TherapeuticsMD in a report on Thursday, April 18th. BidaskClub downgraded shares of TherapeuticsMD from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 16th. ValuEngine lowered shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Wednesday, May 15th. Finally, JPMorgan Chase & Co. cut their price objective on shares of TherapeuticsMD from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. TherapeuticsMD currently has an average rating of “Hold” and an average price target of $11.16.
TXMD stock traded up $0.16 during mid-day trading on Tuesday, hitting $2.54. 84,953 shares of the stock were exchanged, compared to its average volume of 3,187,358. The firm has a market cap of $759.85 million, a P/E ratio of -4.37 and a beta of 2.14. The company has a quick ratio of 3.28, a current ratio of 3.39 and a debt-to-equity ratio of 1.26. TherapeuticsMD has a 12 month low of $2.21 and a 12 month high of $7.42.
Several hedge funds and other institutional investors have recently bought and sold shares of TXMD. FMR LLC grew its position in shares of TherapeuticsMD by 50.1% in the 4th quarter. FMR LLC now owns 18,088,341 shares of the company’s stock valued at $68,917,000 after buying an additional 6,038,353 shares during the last quarter. Frontier Capital Management Co. LLC lifted its stake in shares of TherapeuticsMD by 291.5% in the first quarter. Frontier Capital Management Co. LLC now owns 5,857,096 shares of the company’s stock valued at $28,524,000 after purchasing an additional 4,360,963 shares during the period. Rubric Capital Management LP lifted its stake in shares of TherapeuticsMD by 203.6% in the first quarter. Rubric Capital Management LP now owns 4,690,970 shares of the company’s stock valued at $22,845,000 after purchasing an additional 3,145,742 shares during the period. Millennium Management LLC increased its holdings in TherapeuticsMD by 590.6% during the 4th quarter. Millennium Management LLC now owns 2,848,750 shares of the company’s stock valued at $10,854,000 after acquiring an additional 2,436,259 shares in the last quarter. Finally, Daruma Capital Management LLC increased its holdings in TherapeuticsMD by 11.8% during the 1st quarter. Daruma Capital Management LLC now owns 7,111,035 shares of the company’s stock valued at $34,631,000 after acquiring an additional 750,235 shares in the last quarter. 78.93% of the stock is currently owned by hedge funds and other institutional investors.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.
Featured Article: Does a trade war provide a risk to the global economy?
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.